Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TRDA Entrada Therapeutics, Inc.

已收盘 02-10 16:00:00 EST

10.82

+0.27

+2.56%

盘后10.82

+0.000.00%

16:04 EST

最高11.35	最低10.18	成交量21.09万
今开10.60	昨收10.55	日振幅11.09%
总市值4.14亿	流通市值2.34亿	总股本3,822万
成交额231.51万	换手率0.98%	流通股本2,158万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TRDA","market":"US","secType":"STK","nameCN":"Entrada Therapeutics, Inc.","latestPrice":10.82,"timestamp":1770757200000,"preClose":10.55,"halted":0,"volume":210898,"hourTrading":{"tag":"盘后","latestPrice":10.82,"preClose":10.82,"latestTime":"16:04 EST","volume":264,"amount":2856.48,"timestamp":1770757445817,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.025592417061611333,"floatShares":21582000,"shares":38219232,"eps":-2.51511,"marketStatus":"已收盘","change":0.27,"latestTime":"02-10 16:00:00 EST","open":10.6,"high":11.35,"low":10.18,"amount":2315082.17948,"amplitude":0.1109,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.51511,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":5,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":10.55,"postHourTrading":{"tag":"盘后","latestPrice":10.82,"preClose":10.82,"latestTime":"16:04 EST","volume":264,"amount":2856.48,"timestamp":1770757445817,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.976789,"impliedVol":1.3017,"impliedVolPercentile":0.6853},"requestUrl":"/m/hq/s/TRDA/wiki","defaultTab":"wiki","newsList":[{"id":"1140741050","title":"Entrada Therapeutics计划2026年底前启动ENTR-601-50全球1/2期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1140741050","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140741050?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:12","pubTimestamp":1767874341,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics宣布，预计将在2026年年底前启动其候选药物ENTR-601-50的全球性1/2期多次给药（MAD）临床研究。这一时间表标志着该公司在推进其研发管线方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"gpt_icon":0},{"id":"1161618850","title":"Entrada Therapeutics公司预计2026年第二季度公布Elevate-44-201首组数据，年中披露Elevate-45-201首组数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161618850","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161618850?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:10","pubTimestamp":1767874239,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics Inc（TRDA）宣布其临床研究计划正稳步推进。根据最新时间表，公司将在2026年第二季度公布Elevate-44-201试验首组患者的研究数据，并于2026年年中发布Elevate-45-201试验的首组数据。这两项关键临床数据的披露将为企业后续研发决策提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"gpt_icon":0},{"id":"1154777080","title":"Entrada Therapeutics预计现金使用期延长至2027年第三季度，截止至9月30日现金、现金等价物及可交易证券合计达3.27亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154777080","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154777080?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:25","pubTimestamp":1762431917,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics预计现金使用期延长至2027年第三季度，截止至9月30日现金、现金等价物及可交易证券合计达3.27亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"gpt_icon":0},{"id":"1108613253","title":"Entrada Therapeutics, Inc.宣布根据纳斯达克上市规则5635(C)(4)实施激励性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1108613253","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108613253?lang=zh_cn&edition=full","pubTime":"2025-09-03 06:02","pubTimestamp":1756850528,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics, Inc.宣布根据纳斯达克上市规则5635(C)(4)实施激励性股票授予计划。\n该公司按照相关上市规则要求，对符合条件的人员实施了激励性股票授予。这一举措是公司人才激励策略的重要组成部分。\n根据纳斯达克上市规则5635(C)(4)的规定，上市公司可以在特定条件下向新员工或其他符合条件的人员授予激励性股票，作为招聘和留住人才的重要手段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"gpt_icon":0},{"id":"1142220963","title":"Entrada Therapeutics 2024年第四季度GAAP每股收益$0.03超过预期$(0.67)，销售额$37.40M超过预期$13.12M","url":"https://stock-news.laohu8.com/highlight/detail?id=1142220963","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142220963?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:12","pubTimestamp":1740658350,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics  公布季度每股收益为$0.03，超过分析师一致预期$，超出104.48%。公司季度销售额为$37.40百万，超过分析师一致预期的$13.12百万，超出185.04%。与去年同期$41.85百万的销售额相比，减少了10.63%。以上内容来自Benzinga Earnings专栏，原文如下：Entrada $Therapeutics$  reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $ by 104.48 percent. This is a 110.34 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $37.40 million which beat the analyst consensus estimate of $13.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TRDA"],"gpt_icon":0},{"id":"2478372279","title":"Entrada Therapeutics, Inc.盘中异动 早盘股价大涨5.23%报17.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478372279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478372279?lang=zh_cn&edition=full","pubTime":"2024-10-25 23:07","pubTimestamp":1729868847,"startTime":"0","endTime":"0","summary":"北京时间2024年10月25日23时07分，Entrada Therapeutics, Inc.股票出现波动，股价大幅拉升5.23%。Entrada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.85%。Entrada Therapeutics, Inc.公司简介：Entrada Therapeutics Inc临床阶段生物制药公司，旨在通过建立一类新的药物来改变患者的生活，这些药物涉及长期以来被认为难以接近的细胞内靶点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102523072798e3e89c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102523072798e3e89c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TRDA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.entradatx.com","stockEarnings":[{"period":"1week","weight":-0.1097},{"period":"1month","weight":0.0529},{"period":"3month","weight":0.3701},{"period":"6month","weight":0.9831},{"period":"1year","weight":-0.1847},{"period":"ytd","weight":0.0263}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Entrada Therapeutics, Inc.于2016年9月22日根据特拉华州法律注册成立。该公司旨在通过将内体逃逸载体(EEV)疗法确立为一种新型药物来改变患者的生活，并致力于成为世界上最重要的细胞内疗法公司。该公司的EEV疗法旨在处理长期以来被认为无法接近和无法成药的细胞内靶标。通过其专有的、高度通用的模块化EEV平台，该公司正在构建强大的EEV治疗候选药物开发组合，旨在使治疗剂在各种器官和组织中有效细胞内递送，并提高治疗指数。该公司相信，早期项目的潜在成功可以转化为有效开发其他EEV治疗候选药物，并能够在罕见疾病、免疫学和肿瘤学方面建立投资组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.119802},{"month":2,"riseRate":0.4,"avgChangeRate":-0.027247},{"month":3,"riseRate":0.5,"avgChangeRate":-0.065115},{"month":4,"riseRate":0.25,"avgChangeRate":-0.177334},{"month":5,"riseRate":0.5,"avgChangeRate":0.061748},{"month":6,"riseRate":0.5,"avgChangeRate":0.23206},{"month":7,"riseRate":0.75,"avgChangeRate":0.057246},{"month":8,"riseRate":0.25,"avgChangeRate":-0.040222},{"month":9,"riseRate":0.75,"avgChangeRate":0.071087},{"month":10,"riseRate":1,"avgChangeRate":0.182556},{"month":11,"riseRate":0.6,"avgChangeRate":0.06971},{"month":12,"riseRate":0.4,"avgChangeRate":-0.097654}],"exchange":"NASDAQ","name":"Entrada Therapeutics, Inc.","nameEN":"Entrada Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Entrada Therapeutics, Inc.(TRDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Entrada Therapeutics, Inc.,TRDA,Entrada Therapeutics, Inc.股票,Entrada Therapeutics, Inc.股票老虎,Entrada Therapeutics, Inc.股票老虎国际,Entrada Therapeutics, Inc.行情,Entrada Therapeutics, Inc.股票行情,Entrada Therapeutics, Inc.股价,Entrada Therapeutics, Inc.股市,Entrada Therapeutics, Inc.股票价格,Entrada Therapeutics, Inc.股票交易,Entrada Therapeutics, Inc.股票购买,Entrada Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Entrada Therapeutics, Inc.(TRDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}